Forecasts by the Institute for Health Research (IGSF) predict a steady increase in the annual number of new cases of cardiovascular diseases, age-related diabetes mellitus, osteoporosis, arthrosis, tumors, strokes and dementia. Recognizing these diseases more quickly and treating them more effectively should be among the most urgent medical and social goals. NanoBioMedizin helps to identify the concrete clinical challenges that exist in various diseases and shows how these can be solved by nanobiomedical innovations in diagnostics, therapy or regenerative medicine and which important fields of action exist for this.
The action paper provides a detailed analysis of the conditions for the translation of relevant research results as well as recommendations for action to optimize research and development. Furthermore, the paper deals with clinical issues and nanobiomedical research approaches, particularly with in-vivo and in-vitro diagnostics. Since the social and economic challenges should not be neglected, the expert authors from more than 15 research institutions, pharmaceutical companies and clinics also address this problem in the chapter "Vision 2050 and socio-economic effects" and show that topics such as medical patient relationship of the future or new calculation models for the adjustment of the reimbursement systems will be relevant for your research.
The goals continue to be to create new interdisciplinary research, training and translation structures that involve scientists, technologists, clinicians and SMEs and effectively network with larger industrial companies and regulatory authorities. Overall, the goal is to establish complete nanobiomedical value chains in Germany in order to enable the economic use of nanobiomedicine in Germany in the long term.
The Action Paper 2020 is a further developed version of the paper from 2015. The German Platform NanoBioMedicine was founded in 2015 by representatives from research institutions, industry and authorities. The aim of the initiative is to bring the results of nanobiotechnological research to patients more quickly and effectively and to make Germany scientifically and economically fit for global competition in the future technology of nanobiomedicine.
Source: Press release DECHMA from December 02.12.2020nd, XNUMX